AstraZeneca Reports the Data from P-IIIb (BATURA) Study of Airsupra (Albuterol/Budesonide) for Intermittent or Mild Persistent Asthma
Shots:
- The P-IIIb (BATURA) study is assessing inhaled Airsupra (180mcg/160mcg) vs albuterol (180mcg) as-needed rescue medication for 12mos. in patients (≥12yrs.) with intermittent or mild persistent asthma. Subjects were on as-needed SABA alone or with low-dose ICS/LTRA maintenance therapy
- Study achieved its 1EP, showing reduced risk of severe exacerbation in response to symptoms, with safety & tolerability aligning with the known profiles. Results to be shared with health authorities & highlighted at ACAAI 2024
- Airsupra (developed with Avillion) is approved in the US to prevent bronchoconstriction & reduce exacerbations risk in asthmatic patients (≥18yrs.). It is being developed in P-III trials for adolescents (ACADIA) & Chinese patients (BAIYUN
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca Reports the US FDA’s sNDA Acceptance of Calquence with Priority Review for Mantle Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
